One of these is the 5-HT2A receptor, which has a recently discovered unique characteristic: It dampens incoming visual information, giving our brain more space for internal processes and ...

A study reveals distinct brain circuits that psychedelics activate to reduce anxiety without causing hallucinations in mice.

Neushen Therapeutics Inc. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of depression, schizophrenia, anxiety and post-traumatic stress disorder.

The target of their therapy, the serotonin 5-HT2A receptor, plays an essential role in regulating mood, anxiety, and ...

is a biotechnology company that develops 5-HT2A and 5-HT2C serotonin receptor agonists to treat epilepsy, pain, depression, and PTSD. It leverages its proprietary platform to target serotonin ...

We propose a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. A diverse sample with regard to ethnoracial identity and SES will be ...

Most psychedelic research has focused on a different receptor (5-HT2A), which is what makes them cause hallucinations. But scientists believe 5-HT1A might be a key player in developing better ...

D2 and serotonin 5-HT1A receptors and antagonist activity at 5-HT2A receptors. VRAYLAR forms two major metabolites, desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR), that have in ...